| Ronald C. Petersen | |
|---|---|
| Photo placeholder | |
| Affiliations | Mayo Clinic |
| Country | USA |
| H-index | 220 |
| ORCID | 0000-0002-0188-913X |
| Research Focus | Alzheimer's Disease, Mild Cognitive Impairment, Biomarkers |
| Mechanisms | Amyloid, Tau, Biomarkers, Clinical Trials |
Ronald C. Petersen is a distinguished neurologist and researcher at the Mayo Clinic who has made foundational contributions to our understanding of Alzheimer's disease, particularly in the areas of mild cognitive impairment (MCI) and biomarker development. As director of the Mayo Clinic Alzheimer's Disease Research Center, he has led major initiatives to characterize the preclinical and prodromal stages of Alzheimer's disease.
Dr. Petersen completed his medical training and neurology residency at the Mayo Clinic, where he also pursued research training in cognitive neuroscience. He has served as the director of the Mayo Clinic Alzheimer's Disease Research Center for over two decades and has been a leading figure in defining the concept of mild cognitive impairment as a precursor to Alzheimer's disease.
Dr. Petersen pioneered the characterization of MCI as a distinct clinical entity:
His biomarker research has focused on:
Dr. Petersen has been instrumental in:
His work has resulted in over 500 peer-reviewed publications, including seminal papers on MCI diagnostic criteria and biomarker validation.
Dr. Petersen has established numerous collaborative research networks:
These collaborations have enabled the largest-ever studies of preclinical and prodromal Alzheimer's disease, with data shared across hundreds of researchers worldwide.
His work continues to drive advances in understanding and treating these devastating diseases, with ongoing studies exploring novel therapeutic approaches and early intervention strategies. These efforts have significantly improved our ability to diagnose, monitor, and treat patients with neurodegenerative conditions.
In addition to his research contributions, Dr. Petersen maintains an active clinical practice seeing patients with memory disorders. He emphasizes the importance of early diagnosis and intervention, working with patients and families to develop comprehensive care plans that incorporate both pharmacological and lifestyle approaches to managing cognitive decline.
His clinical work has informed his research priorities, ensuring that scientific discoveries are translated into practical applications that benefit patients immediately.